source
- Licensing deals with Chinese biotech stay strong as big pharma pours $550M+ into cancer and obesity pipelinesWestern drug developers continue to sign licensing agreements with Chinese biotechnology firms at a steady pace, according to recent data visualizations. More than 100 such deals have been announc…
- Truist sees biotech rebound as M&A hits $136B and XBI climbs 34% in H1Truist Securities says the biotech sector is regaining momentum after a prolonged post‑pandemic slowdown, driven by rising merger activity, returning venture capital and easing policy risks. The S…